

Molecular Health launches MH Mendel for the genetic diagnosis of hereditary diseases

- *MH Mendel combines the most relevant information for the diagnosis of hereditary diseases*
- *MH Mendel helps patients and supports physicians through most modern and comprehensive precision medicine technologies and expertise*
- *MH Mendel becomes an integral part of IVD registered Molecular Health Guide® 3.0*

Heidelberg, Germany and Boston, USA - June 11, 2018 – Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer cancer treatment options based on its proprietary Dataome® technology platform, has introduced Molecular Health Guide® Mendel (MH Mendel) as part of the established Molecular Health Guide® (MH Guide), a comprehensive software solution for precision medicine. MH Mendel, an integral part of the MH Guide 3.0, a registered IVD product, supports human geneticists in creating a diagnostic report based on their own variant classifications. MH Mendel combines the information that is most relevant for the diagnosis of hereditary diseases.

Data from a variety of sources are provided to help human geneticists to assess and classify variants detected in their patients. MH Mendel includes population frequencies, reported clinical significance, and functional impact predictions for a plethora of variants. For analysis of germline variants associated with hereditary diseases, MH Mendel supports human geneticists in managing their own variant classifications and interpretations as well as in creating diagnostic reports.

"Genetic tests can reveal a predisposition to rare hereditary diseases. Today some hereditary diseases can be managed. Early detection and precise understanding is important to initiate treatment and to prevent avoidable irreparable defects. Results of genetic tests analyzed and evaluated by MH Mendel can reveal a predisposition to diseases and help physicians to find the exact molecular cause and to create a personalized diagnostic report for each patient", says Dr. Stephan Brock, CTO of Molecular Health. "We are glad that with MH Mendel we can now help patients and support physicians with our advanced and highly curated and integrated precision medicine technologies and expertise."

About Molecular Health

Molecular Health (MH) is a computational biomedicine company focused on the capture, curation, integration, and analysis of large data sets in the field of biomedicine and medical products and combining them with novel artificial intelligence and machine learning (AI/ML) technologies to enable precision medicine. Over more than a decade, the company has developed Dataome®, a unique, high-quality curated, interoperable system that combines clinico-molecular drug data and analytical processes. Dataome, in combination with novel AI/ML technologies, creates a totally new approach for prognostic and predictive in silico science that can guide some of the most promising yet most challenging domains of precision medicine.

For more information, visit www.molecularhealth.com

Carla Mertens
Molecular Health GmbH

Carla.mertens@molecularhealth.com